HIMSHims & Hers Health, Inc.
Price
-47%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, undemanding price, growth steady, the market undecided.
We are a consumer-first health and wellness platform focused on providing access to modern personalized health and wellness solutions to consumers. We offer access to a range of health and wellness products and services available for customers to purchase through our websites and mobile applications. The offerings generally focus on conditions where treatment typically involves use of prescription medication on a recurring basis and ongoing care from healthcare providers.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Hims & Hers Health, Inc. (HIMS) reported revenue of $753M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 64% and net loss of $86M. For the full year FY2025, revenue was $2.35B (+59% year on year) and net income $128M. Its largest region in Q2 2026 was United States at $622M, 83% of the disclosed total, well ahead of Non Us at 17%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026On October 5, 2026, Jonathan M. Franklin commenced employment with Hims & Hers Health, Inc. (the “Company”) as chief accounting officer.Director or officer change · Form 8-K
- Jul 17, 2026On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the “Company”) of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026.Director or officer change · Form 8-K
- Jul 1, 2026Receivables Purchase Agreement On July 1, 2026, XeCare LLC and Apostrophe Pharmacy LLC (collectively, the “Sellers”), subsidiaries of Hims & Hers Health, Inc. (the “Company”), entered into a Master Receivables Purchase Agreement (the “RPA”) with JPMorgan Chase Bank, N.A., as purchaser (in such capacity, the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $753.2MThe company’s own SEC segment disclosure.
- United States$621.8M83%
- Non Us$131.4M17%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #36 of 41 by RyuScore